The Use of Rituximab with Immune Tolerance Induction Therapy for Hemophilia A with Inhibitors / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 67-71, 2015.
Article
Dans Anglais
| WPRIM
| ID: wpr-13541
ABSTRACT
Inhibitor development is one of the major adverse events associated with increased morbidity and mortality in patients with congenital hemophilia. Recent treatment for them is immune tolerance induction (ITI), which involves the administration of high doses of factor concentrates over a prolonged period, sometimes combined with immunosuppressive agents. We report a case of inhibitor elimination with Rituximab, and high-dose factor VIII concentrates in a 5-year-old boy with hemophilia A. The patient improved clinically, with fewer bleeding episodes. However, he continued to have low immunoglobulin levels, which led to recurrent infections. After an infusion of intravenous immunoglobulin, inhibitor titers increased rapidly and his ITI was deemed a failure. In conclusion, even though it failed in the present study, Rituximab may be an alternative adjuvant therapy to eliminate the inhibitor in patients with hemophilia. The appropriate schedule and long-term side effects need further investigation.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Rendez-vous et plannings
/
Facteur VIII
/
Immunoglobulines
/
Mortalité
/
Rituximab
/
Hémophilie A
/
Hémorragie
/
Tolérance immunitaire
/
Immunosuppresseurs
Type d'étude:
Étude pronostique
Limites du sujet:
Enfant d'âge préscolaire
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Clinical Pediatric Hematology-Oncology
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS